A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: Cognitive improvement correlates with qEEG acceleration

Mureșanu, Dafin F.; Alvarez, X.A.; Moessler, Herbert; Buia, M.R.; Stan, Adina; Pintea, Daniela; Moldovan, Florina; Popescu, Bogdan Ovidiu

doi:10.1016/j.jns.2007.10.016

Cited by 35 publications

(35 citation statements)

References 41 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A lower EEG-power ratio both for deep sleep periods 1 and 2 of the cognitive induction night in comparison with the reference night was observed. As stated before, an increase in the EEG-power ratio applied, reflects a slowing of the EEG, whereas a decrease in EEG-power ratio is indicative of an EEG-acceleration (Muresanu et al, 2008). Also an increase in relative power in the high frequency EEG bands was found in the night 2,0 1,9 1,8 1,7 1,6 1,5 1,4 1,3 1,2 1,1 1,0 0,9 0,8 0,7 0,6 0,5 0,4 0,3 0,2 0,1…”

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

The influence of pre-sleep cognitive arousal on sleep onset processes

Wuyts,

De Valck,

Vandekerckhove

et al. 2012

International Journal of Psychophysiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 66%

“…This was performed for the first and second DS-period of each REF-and COG-night. An increase in EEG-PR reflects a slowing of the EEG, whereas a decrease in EEG-PR is indicative of an EEG-acceleration (Muresanu et al, 2008).…”

Section: Polysomnography (Psg) Fast Fourier Analyses Heart Rate Prmentioning

confidence: 99%

The influence of pre-sleep cognitive arousal on sleep onset processes

Wuyts,

De Valck,

Vandekerckhove

et al. 2012

International Journal of Psychophysiology

View full text Add to dashboard Cite

“…Only three studies (of which two have completed) have used EEG, although, interestingly, both showed a change in EEG in the treated group. 40,109 There are too few data to draw any conclusions, but both EEG (and magnetoencephalography) and functional MRI merit further investigation and validation in future studies, especially those undertaken over short treatment periods (4-26 weeks).…”

Section: Biological Markers: Imagingmentioning

confidence: 99%

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Webster

Groskreutz

Grinbergs-Saull

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Background: There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriate outcomes for disease modification would facilitate the design of trials and ensure consistency across disease modification trials, as well as making results comparable and meta-analysable in future trials. Objectives: To agree a set of core outcomes for disease modification trials for mild to moderate dementia with the UK dementia research community and patient and public involvement (PPI). Data sources: We included disease modification trials with quantitative outcomes of efficacy from (1) references from related systematic reviews in workstream 1; (2) searches of the Cochrane Dementia and Cognitive Improvement Group study register, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, EMBASE, Latin American and Caribbean Health Sciences Literature and PsycINFO on 11 December 2015, and clinical trial registries [International Standard Randomised Controlled Trial Number (ISRCTN) and clinicaltrials.gov] on 22 and 29 January 2016; and (3) hand-searches of reference lists of relevant systematic reviews from database searches. Review methods: The project consisted of four workstreams. (1) We obtained related core outcome sets and work from co-applicants. (2) We systematically reviewed published and ongoing disease modification trials to identify the outcomes used in different domains. We extracted outcomes used in each trial, recording how many used each outcome and with how many participants. We divided outcomes into the domains measured and searched for validation data. (3) We consulted with PPI participants about recommended outcomes. (4) We presented all the synthesised information at a conference attended by the wider body of National Institute for Health Research (NIHR) dementia researchers to reach consensus on a core set of outcomes. Results: We included 149 papers from the 22,918 papers screened, referring to 125 individual trials. Eighty-one outcomes were used across trials, including 72 scales [31 cognitive, 12 activities of daily living (ADLs), 10 global, 16 neuropsychiatric and three quality of life] and nine biological techniques. We consulted with 18 people for PPI. The conference decided that only cognition and biological markers are core measures of disease modification. Cognition should be measured by the Mini Mental State Examination (MMSE) or the Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog), and brain changes through structural magnetic resonance imaging (MRI) in a subset of participants. All other domains are important but not core. We recommend using the Neuropsychiatric Inventory for neuropsychiatric symptoms: the Disability Assessment for Dementia for ADLs, the Dementia Quality of Life Measure for quality of life and the Clinical Dementia Rating scale to measure dementia globally. Limitations: Most of the trials inclu...

show abstract

“…There is evidence that visual and quantitative analyses of EEG traces can be used to differentiate between Alzheimer's and vascular dementia (Gawel 2009). Quantitative EEG findings indicate that increased EEG slowing is associated with a poorer cognitive performance in patients with vascular dementia (Muresanu 2008).…”

Section: Dementiamentioning

confidence: 99%

EEG in psychiatric practice: to do or not to do?

Badrakalimuthu¹,

Swamiraju²,

Waal³

2011

Adv. psychiatr. treat

View full text Add to dashboard Cite

SummaryElectroencephalography (EEG) is a non-invasive investigation that can aid the diagnosis of psychiatric and neuropsychiatric disorders. A good predictor of an abnormal EEG recording is the presence of an organic factor identified during the clinical assessment. The non-invasiveness and low cost of the procedure and its ability to measure spontaneous brain activity appear to attract clinicians to utilise this investigative tool. However, studies have reported that EEGs arising from psychiatric referrals have the lowest abnormality detection rate. The focus of this article is to improve this by highlighting the current pitfalls and providing recommendations for appropriate utilisation of EEG. We describe specific EEG changes associated with major psychiatric disorders. We conclude by offering pragmatic considerations when referring a patient for EEG, emphasising the fact that the information provided to the neurophysiologist plays a crucial role in interpreting the EEG recording in a diagnostically meaningful way.

show abstract

A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: Cognitive improvement correlates with qEEG acceleration

Cited by 35 publications

References 41 publications

The influence of pre-sleep cognitive arousal on sleep onset processes

The influence of pre-sleep cognitive arousal on sleep onset processes

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

EEG in psychiatric practice: to do or not to do?

Contact Info

Product

Resources

About